Thromb Haemost 1985; 53(01): 118-121
DOI: 10.1055/s-0038-1661249
Original Article
Schattauer GmbH Stuttgart

The Effect of Diabetes Regulation on Platelet Release, Fibrinolysis and Coagulation Tests, Before and After Stimulation with DDAVP

J H v d Knaap
The Municipal Hospital Bergweg, Rotterdam, The Netherlands
,
A C de Boer
The Municipal Hospital Bergweg, Rotterdam, The Netherlands
,
M A G Pannebakker
The Municipal Hospital Bergweg, Rotterdam, The Netherlands
,
W van Heerde
The Municipal Hospital Bergweg, Rotterdam, The Netherlands
,
G J H den Ottolander
The Municipal Hospital Bergweg, Rotterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 14 August 1984

Accepted 26 November 1984

Publication Date:
18 July 2018 (online)

Summary

In this longitudinal study we measured β-TG, PF4, fibrinolytic activity (extrinsic and euglobulin fraction), fibrinogen, FVIII RAg and FVIII Rcof before and after i.v. DDAVP (FPA was only measured before DDAVP) in 20 patients with diabetes mellitus. These parameters were measured on three occasions: phase I: during disregulation, phase II: after three weeks of strict control, phase III: after nine weeks of good control. Twenty-two healthy volunteers served as normal controls.

No significant differences related to metabolic control were found for β-TG, PF4, FPA and fibrinogen. There was no change after i.v. DDAVP administration. Fibrinolytic activity showed a significant increase after i.v. DDAVP. Baseline values and post-DDAVP increase were not significantly different from our normal controls.

FVIII RAg and FVIII Rcof were both significantly elevated in diabetes mellitus. Both increased significantly after DDAVP. The FVIII RAg release (ΔFVIII RAg) was significantly less in the diabetics. Fibrinolytic activity, FVIII RAg and FVIII Rcof are independent of the degree of metabolic control in patients with diabetes.

 
  • References

  • 1 Bern MM, Cassani MP, Horton J, Land L, Davis G. Changes of fibrinolysis and factor VIII coagulant, antigen and ristocetin cofactor in diabetes mellitus and atherosclerosis. Thromb Res 1980; 19: 831-839
  • 2 Elder GE, Mayne EE, Daly JG, Kennedy AL, Hadden DR, Montgomery DA D, Waever JA. Antithrombin III activity and other coagulation changes in proliferative diabetic retinopathy. Haemostasis 1980; 9: 288-296
  • 3 Aimer LO, Lilja B, Lindell SE, Nilsson IM. Endothelial factors in relation to peripheral circulation in diabetics. Thromb Res 1980; 20: 231-238
  • 4 Aimer LO, Nilsson IM. On fibrinolysis in Diabetes Mellitus. Acta Med Scand 1975; 198: 101-106
  • 5 Aimer LO, Pandolfi M, Nilsson IM. Diabetic retinopathy and the fibrinolytic system. Diabetes 1975; 24: 529-534
  • 6 Dalsgaard-Nielsen J, Madsbad S, Hilsted J. Changes in platelet function, blood coagulation and fibrinolysis during insulin-induced hyperglycemia in juvenile diabetics and normal subjects. Thromb Haemostas 1982; 47: 254-258
  • 7 Gunnarsson R, Nijman D, Walinder O, Ostman J. Fibrinolytic activity and diabetes control - evidence for a relationship. Acta Med Scand 1980; (Suppl. 639) (suppl) 23-24
  • 8 Kluft C. Blood fibrinolysis. Thesis Leiden: 1983
  • 9 Kluft C, Jie AF, Allen RA. Behaviour and quantification of extrinsic (tissue-type) plasminogen activator in human blood. Thromb Haemostas 1983; 50: 518-523
  • 10 Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of FVIII von Willebrand to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand’s disease. Br J Haematol 1981; 47: 283-293
  • 12 Kluft C. Cl-inactivator-resistant fibrinolytic activity in plasma euglobulin fractions. Thromb Res 1978; 13: 135-151
  • 13 Kluft C. Studies on the fibrinolytic system in human plasma: quantitative determination of plasminogen activators and proactivators. Thromb Haemostas 1979; 41: 365-383
  • 14 Zuzel M, Nilsson IM, Aberg M. A method for measuring plasma ristocetin cofactor activity. Thromb Res 1978; 12: 745-754
  • 15 Han P, Butt RW, Turpie AG, Walker WH, Genton E. p-thromboglobulin radioimmunoassays, a laboratory characterisation and evaluation. J Immunoassay 1980; 1: 211-227
  • 16 Lufkin EG, Fass DN, O’Fallow WM, Bowie EJ W. Increased von Willebrand factor in diabetes mellitus. Metabolism 1979; 28: 63-66
  • 17 Coller BS, Frank RN, Milton RC, Gralnick HR. Plasma cofactors of platelet function: Correlation with diabetic retinopathy and hemoglobins Ala-c. Ann Int Med 1978; 88: 311-316
  • 18 Gensini GF, Abbate R, Favilla S, Neri Semeri GG. Changes of platelet function and blood clotting in diabetes mellitus. Thromb Haemostas 1979; 42: 983-993
  • 19 Giustolisi R, Musso R, Russo M, Catania N, Lombardo T, Cacciola E. Possible evidence for an increased factor VIII antigen synthesis in vascular endothelial of diabetic subjects. Thromb Haemostas 1982; 47: 293
  • 20 Brooks AM V, Hussein S, Chesterman CN, Martin JF, Alford FP, Pennington DG. Platelets, coagulation and fibrinolysis in patients with diabetic retinopathy. Thromb Haemostas 1983; 49: 123-127
  • 21 Rak K, Beck P, Udvardy M, Pflieger G, Misz M, Boda Z. Plasma levels of beta-thromboglobulin and factor VHI-related antigen in diabetic children and adults. Thromb Res 1983; 29: 155-162
  • 22 Vicente Garcia V, Alberca Silva I, Lopez Borrasca A. Response of factor VIH/von Willebrand factor to intranasal DDAVP in healthy subjects and mild haemophiliacs (with observations in patients with combined deficiency of factors V and VII). Thromb Haemostas 1982; 48: 91-93
  • 23 Giustolisi R, Lombardo T, Musso R, Cacciola E. Factor VIII antigen plasma levels in diabetes mellitus. Enhanced endothelial release and storage Thromb Haemostas 1980; 44: 46
  • 24 Mannucci PM, Pareti FI, Ruggeri ZM, Capitanio A. 1-desamino-8-D-arginine-vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand’s disease. Lancet 1977; 1: 869-872
  • 25 Prowse CV, Farrugia A, Boulton FE, Tucker J, Ludlam CA, McLaren M, Belch JJ F, Prentice CR M, Dawes J, MacGregor IR. A comparative study using immunological and biological assays of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men. Thromb Haemostas 1984; 51: 110-114
  • 26 Vicente V, Alberca I, Mannucci PM. Reduced effect of exercise and DDAVP on factor VIII-von Willebrand factor and plasminogen activator after sequential application of both the stimuli. Thromb Haemostas 1984; 51: 129-130
  • 27 Juhan-Vague I, Rijken DC, De Cock F, Mendes C, Collen D. Extrinsic plasminogen activator levels in clinical plasma samples. In: Progress in fibrinolysis. Davidson JF, Bachman F, Bouvier CA, Kruithof EK O. (Eds) Churchill-Livingstone; Edinburgh, London, Melbourne, New York: 1983. 6 65-69
  • 28 Borsey DQ, Prowse CV, Gray RS, Dawes J, James K, Elton RA, Clarke BF. Platelet and coagulation factors in proliferative diabetic retinopathy. J Clin Pathol 1984; 37: 659-664
  • 29 Burrows AW, Chavin SI, Hockaday T DR. Plasma thromboglobulin concentrations in diabetes mellitus. Lancet 1978; 1: 235-237
  • 30 Van Oost BA, Veldhuyzen BF E, Van Houwelingen HC, Timmermans AP M, Sixma JJ. Tests for platelet changes, acte phase reactants and serum lipids in diabetes mellitus and peripheral vascular disease. Thromb Haemostas 1982; 48: 289-293